Effects of rituximab in connective tissue disorders related interstitial lung disease.
Identifieur interne : 001854 ( PubMed/Corpus ); précédent : 001853; suivant : 001855Effects of rituximab in connective tissue disorders related interstitial lung disease.
Auteurs : Gemma Lepri ; Jerome Avouac ; Paolo Air ; Francisco Anguita Santos ; Silvia Bellando-Randone ; Jelena Blagojevic ; Francisco Garcia Hernàndez ; Jose Antonio Gonzalez Nieto ; Serena Guiducci ; Suzana Jordan ; Vidya Limaye ; Britta Maurer ; Albert Selva-O'Callaghan ; Valeria Riccieri ; Oliver Distler ; Marco Matucci-Cerinic ; Yannick AllanoreSource :
- Clinical and experimental rheumatology [ 0392-856X ]
English descriptors
- KwdEn :
- Adult, Aged, Connective Tissue Diseases (complications), Connective Tissue Diseases (diagnosis), Connective Tissue Diseases (drug therapy), Disease Progression, Female, Humans, Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Lung (drug effects), Lung (physiopathology), Lung Diseases, Interstitial (diagnosis), Lung Diseases, Interstitial (drug therapy), Lung Diseases, Interstitial (etiology), Lung Diseases, Interstitial (physiopathology), Male, Middle Aged, Recovery of Function, Respiratory Function Tests, Retrospective Studies, Rituximab (adverse effects), Rituximab (therapeutic use), Time Factors, Treatment Outcome, Vital Capacity.
- MESH :
- chemical , adverse effects : Immunosuppressive Agents, Rituximab.
- complications : Connective Tissue Diseases.
- diagnosis : Connective Tissue Diseases, Lung Diseases, Interstitial.
- drug effects : Lung.
- drug therapy : Connective Tissue Diseases, Lung Diseases, Interstitial.
- etiology : Lung Diseases, Interstitial.
- physiopathology : Lung, Lung Diseases, Interstitial.
- chemical , therapeutic use : Immunosuppressive Agents, Rituximab.
- Adult, Aged, Disease Progression, Female, Humans, Male, Middle Aged, Recovery of Function, Respiratory Function Tests, Retrospective Studies, Time Factors, Treatment Outcome, Vital Capacity.
Abstract
Interstitial lung disease (ILD) is a key prognostic factor in connective tissue disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional tests (PFTs) in various CTDs, including anti-synthetase syndrome (SYN), systemic sclerosis (SSc) and mixed connective tissue disorder (MCTD), following the use of rituximab therapy.
PubMed: 27749242
Links to Exploration step
pubmed:27749242Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effects of rituximab in connective tissue disorders related interstitial lung disease.</title><author><name sortKey="Lepri, Gemma" sort="Lepri, Gemma" uniqKey="Lepri G" first="Gemma" last="Lepri">Gemma Lepri</name><affiliation><nlm:affiliation>Dept. of Clinical and Experimental Medicine, AOUC, University of Florence, Italy; and Paris Descartes University, Rheumatology A Dept., APHP, Cochin Hospital, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Avouac, Jerome" sort="Avouac, Jerome" uniqKey="Avouac J" first="Jerome" last="Avouac">Jerome Avouac</name><affiliation><nlm:affiliation>Paris Descartes University, Rheumatology A Department, APHP, Cochin Hospital, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Air, Paolo" sort="Air, Paolo" uniqKey="Air P" first="Paolo" last="Air">Paolo Air</name><affiliation><nlm:affiliation>Spedali Civili di Brescia, Service of Rheumatology and Clinical Immunology, University of Brescia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Anguita Santos, Francisco" sort="Anguita Santos, Francisco" uniqKey="Anguita Santos F" first="Francisco" last="Anguita Santos">Francisco Anguita Santos</name><affiliation><nlm:affiliation>Hospital Clinico San Cecilio, Granada, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</nlm:affiliation></affiliation></author><author><name sortKey="Bellando Randone, Silvia" sort="Bellando Randone, Silvia" uniqKey="Bellando Randone S" first="Silvia" last="Bellando-Randone">Silvia Bellando-Randone</name><affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Blagojevic, Jelena" sort="Blagojevic, Jelena" uniqKey="Blagojevic J" first="Jelena" last="Blagojevic">Jelena Blagojevic</name><affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Garcia Hernandez, Francisco" sort="Garcia Hernandez, Francisco" uniqKey="Garcia Hernandez F" first="Francisco" last="Garcia Hernàndez">Francisco Garcia Hernàndez</name><affiliation><nlm:affiliation>Hospital Virgen del Rocio, Department of Internal Medicine, Sevilla, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez Nieto, Jose Antonio" sort="Gonzalez Nieto, Jose Antonio" uniqKey="Gonzalez Nieto J" first="Jose Antonio" last="Gonzalez Nieto">Jose Antonio Gonzalez Nieto</name><affiliation><nlm:affiliation>Hospital Can Misses, Autoimmune Disease Unit, Internal Medicine, Ibiza, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</nlm:affiliation></affiliation></author><author><name sortKey="Guiducci, Serena" sort="Guiducci, Serena" uniqKey="Guiducci S" first="Serena" last="Guiducci">Serena Guiducci</name><affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Jordan, Suzana" sort="Jordan, Suzana" uniqKey="Jordan S" first="Suzana" last="Jordan">Suzana Jordan</name><affiliation><nlm:affiliation>Department of Rheumatology, University Hospital Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Limaye, Vidya" sort="Limaye, Vidya" uniqKey="Limaye V" first="Vidya" last="Limaye">Vidya Limaye</name><affiliation><nlm:affiliation>Royal Adelaide Hospital, University of Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Maurer, Britta" sort="Maurer, Britta" uniqKey="Maurer B" first="Britta" last="Maurer">Britta Maurer</name><affiliation><nlm:affiliation>Department of Rheumatology, University Hospital Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Selva O Callaghan, Albert" sort="Selva O Callaghan, Albert" uniqKey="Selva O Callaghan A" first="Albert" last="Selva-O'Callaghan">Albert Selva-O'Callaghan</name><affiliation><nlm:affiliation>Vall D'Hebron General Hospital, Autonoma Univeristy of Barcelona, Internal Medicine, Barcelona, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</nlm:affiliation></affiliation></author><author><name sortKey="Riccieri, Valeria" sort="Riccieri, Valeria" uniqKey="Riccieri V" first="Valeria" last="Riccieri">Valeria Riccieri</name><affiliation><nlm:affiliation>Sapienza University of Rome, Department of Internal Medicine and Medical Specialities, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Distler, Oliver" sort="Distler, Oliver" uniqKey="Distler O" first="Oliver" last="Distler">Oliver Distler</name><affiliation><nlm:affiliation>Department of Rheumatology, University Hospital Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Matucci Cerinic, Marco" sort="Matucci Cerinic, Marco" uniqKey="Matucci Cerinic M" first="Marco" last="Matucci-Cerinic">Marco Matucci-Cerinic</name><affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Allanore, Yannick" sort="Allanore, Yannick" uniqKey="Allanore Y" first="Yannick" last="Allanore">Yannick Allanore</name><affiliation><nlm:affiliation>Paris Descartes University, Rheumatology A Department, APHP, Cochin Hospital, Paris, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="????"><PubDate><MedlineDate>2016 Sep-Oct</MedlineDate></PubDate></date><idno type="RBID">pubmed:27749242</idno><idno type="pmid">27749242</idno><idno type="wicri:Area/PubMed/Corpus">001854</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001854</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Effects of rituximab in connective tissue disorders related interstitial lung disease.</title><author><name sortKey="Lepri, Gemma" sort="Lepri, Gemma" uniqKey="Lepri G" first="Gemma" last="Lepri">Gemma Lepri</name><affiliation><nlm:affiliation>Dept. of Clinical and Experimental Medicine, AOUC, University of Florence, Italy; and Paris Descartes University, Rheumatology A Dept., APHP, Cochin Hospital, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Avouac, Jerome" sort="Avouac, Jerome" uniqKey="Avouac J" first="Jerome" last="Avouac">Jerome Avouac</name><affiliation><nlm:affiliation>Paris Descartes University, Rheumatology A Department, APHP, Cochin Hospital, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Air, Paolo" sort="Air, Paolo" uniqKey="Air P" first="Paolo" last="Air">Paolo Air</name><affiliation><nlm:affiliation>Spedali Civili di Brescia, Service of Rheumatology and Clinical Immunology, University of Brescia, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Anguita Santos, Francisco" sort="Anguita Santos, Francisco" uniqKey="Anguita Santos F" first="Francisco" last="Anguita Santos">Francisco Anguita Santos</name><affiliation><nlm:affiliation>Hospital Clinico San Cecilio, Granada, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</nlm:affiliation></affiliation></author><author><name sortKey="Bellando Randone, Silvia" sort="Bellando Randone, Silvia" uniqKey="Bellando Randone S" first="Silvia" last="Bellando-Randone">Silvia Bellando-Randone</name><affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Blagojevic, Jelena" sort="Blagojevic, Jelena" uniqKey="Blagojevic J" first="Jelena" last="Blagojevic">Jelena Blagojevic</name><affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Garcia Hernandez, Francisco" sort="Garcia Hernandez, Francisco" uniqKey="Garcia Hernandez F" first="Francisco" last="Garcia Hernàndez">Francisco Garcia Hernàndez</name><affiliation><nlm:affiliation>Hospital Virgen del Rocio, Department of Internal Medicine, Sevilla, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</nlm:affiliation></affiliation></author><author><name sortKey="Gonzalez Nieto, Jose Antonio" sort="Gonzalez Nieto, Jose Antonio" uniqKey="Gonzalez Nieto J" first="Jose Antonio" last="Gonzalez Nieto">Jose Antonio Gonzalez Nieto</name><affiliation><nlm:affiliation>Hospital Can Misses, Autoimmune Disease Unit, Internal Medicine, Ibiza, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</nlm:affiliation></affiliation></author><author><name sortKey="Guiducci, Serena" sort="Guiducci, Serena" uniqKey="Guiducci S" first="Serena" last="Guiducci">Serena Guiducci</name><affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Jordan, Suzana" sort="Jordan, Suzana" uniqKey="Jordan S" first="Suzana" last="Jordan">Suzana Jordan</name><affiliation><nlm:affiliation>Department of Rheumatology, University Hospital Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Limaye, Vidya" sort="Limaye, Vidya" uniqKey="Limaye V" first="Vidya" last="Limaye">Vidya Limaye</name><affiliation><nlm:affiliation>Royal Adelaide Hospital, University of Adelaide, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Maurer, Britta" sort="Maurer, Britta" uniqKey="Maurer B" first="Britta" last="Maurer">Britta Maurer</name><affiliation><nlm:affiliation>Department of Rheumatology, University Hospital Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Selva O Callaghan, Albert" sort="Selva O Callaghan, Albert" uniqKey="Selva O Callaghan A" first="Albert" last="Selva-O'Callaghan">Albert Selva-O'Callaghan</name><affiliation><nlm:affiliation>Vall D'Hebron General Hospital, Autonoma Univeristy of Barcelona, Internal Medicine, Barcelona, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</nlm:affiliation></affiliation></author><author><name sortKey="Riccieri, Valeria" sort="Riccieri, Valeria" uniqKey="Riccieri V" first="Valeria" last="Riccieri">Valeria Riccieri</name><affiliation><nlm:affiliation>Sapienza University of Rome, Department of Internal Medicine and Medical Specialities, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Distler, Oliver" sort="Distler, Oliver" uniqKey="Distler O" first="Oliver" last="Distler">Oliver Distler</name><affiliation><nlm:affiliation>Department of Rheumatology, University Hospital Zurich, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Matucci Cerinic, Marco" sort="Matucci Cerinic, Marco" uniqKey="Matucci Cerinic M" first="Marco" last="Matucci-Cerinic">Marco Matucci-Cerinic</name><affiliation><nlm:affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Allanore, Yannick" sort="Allanore, Yannick" uniqKey="Allanore Y" first="Yannick" last="Allanore">Yannick Allanore</name><affiliation><nlm:affiliation>Paris Descartes University, Rheumatology A Department, APHP, Cochin Hospital, Paris, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical and experimental rheumatology</title><idno type="ISSN">0392-856X</idno></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult</term><term>Aged</term><term>Connective Tissue Diseases (complications)</term><term>Connective Tissue Diseases (diagnosis)</term><term>Connective Tissue Diseases (drug therapy)</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Lung (drug effects)</term><term>Lung (physiopathology)</term><term>Lung Diseases, Interstitial (diagnosis)</term><term>Lung Diseases, Interstitial (drug therapy)</term><term>Lung Diseases, Interstitial (etiology)</term><term>Lung Diseases, Interstitial (physiopathology)</term><term>Male</term><term>Middle Aged</term><term>Recovery of Function</term><term>Respiratory Function Tests</term><term>Retrospective Studies</term><term>Rituximab (adverse effects)</term><term>Rituximab (therapeutic use)</term><term>Time Factors</term><term>Treatment Outcome</term><term>Vital Capacity</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Immunosuppressive Agents</term><term>Rituximab</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Connective Tissue Diseases</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Connective Tissue Diseases</term><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Lung</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Connective Tissue Diseases</term><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Lung</term><term>Lung Diseases, Interstitial</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunosuppressive Agents</term><term>Rituximab</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>Disease Progression</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Recovery of Function</term><term>Respiratory Function Tests</term><term>Retrospective Studies</term><term>Time Factors</term><term>Treatment Outcome</term><term>Vital Capacity</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Interstitial lung disease (ILD) is a key prognostic factor in connective tissue disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional tests (PFTs) in various CTDs, including anti-synthetase syndrome (SYN), systemic sclerosis (SSc) and mixed connective tissue disorder (MCTD), following the use of rituximab therapy.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">27749242</PMID><DateCreated><Year>2016</Year><Month>10</Month><Day>17</Day></DateCreated><DateCompleted><Year>2017</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">0392-856X</ISSN><JournalIssue CitedMedium="Print"><Volume>34 Suppl 100</Volume><Issue>5</Issue><PubDate><MedlineDate>2016 Sep-Oct</MedlineDate></PubDate></JournalIssue><Title>Clinical and experimental rheumatology</Title><ISOAbbreviation>Clin. Exp. Rheumatol.</ISOAbbreviation></Journal><ArticleTitle>Effects of rituximab in connective tissue disorders related interstitial lung disease.</ArticleTitle><Pagination><MedlinePgn>181-185</MedlinePgn></Pagination><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="OBJECTIVE">Interstitial lung disease (ILD) is a key prognostic factor in connective tissue disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional tests (PFTs) in various CTDs, including anti-synthetase syndrome (SYN), systemic sclerosis (SSc) and mixed connective tissue disorder (MCTD), following the use of rituximab therapy.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">A multicentre retrospective analysis of patients with ILD secondary to SYN (n=15), MCTD (n=6) and SSc (n=23). PFTs were performed at baseline and at 1 and 2 years of follow-up. The primary outcome was the change in forced vital capacity (FVC) at 1 year.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">In the SYN population, median FVC changed from 53.0% (42.0-90.0) at baseline to 51.4% (45.6-85.0) at 1 year and 63.0 (50-88) (p=0.6) at 2 years (p=0.14). In SSc, FVC changed from 81.0% (66.0-104.0) at baseline to 89.0% (65.0-113.0) at 1 year (p=0.1) and 74.5 (50-91) at 2 years (p=0.07). In the MCTD population, FVC changed from 64.5% (63.0-68.0) at baseline to 63.0% (59.0-71.0) at 1 year (p=0.6) and 61 (59-71) after 2 years (p=0.8). DLCO showed a trend for improvement in the SYN population (p=0.06 at 1 year and 0.2 at years) while changes remain non-significant in the SSc and MCTD patients. In SYN patients, the percentage of responders at 1 year for FVC (33.3%) was greater than in SSc (9.5%) (p=0.07) and MCTD (17%) (p=0.45). RTX showed a satisfactory safety profile.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">A trend of improvement of PFTs was observed in SYN patients although not reaching significance, while SSc and MCTD patients were stabilised.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lepri</LastName><ForeName>Gemma</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Dept. of Clinical and Experimental Medicine, AOUC, University of Florence, Italy; and Paris Descartes University, Rheumatology A Dept., APHP, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avouac</LastName><ForeName>Jerome</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Paris Descartes University, Rheumatology A Department, APHP, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Airò</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Spedali Civili di Brescia, Service of Rheumatology and Clinical Immunology, University of Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anguita Santos</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hospital Clinico San Cecilio, Granada, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellando-Randone</LastName><ForeName>Silvia</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blagojevic</LastName><ForeName>Jelena</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia Hernàndez</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hospital Virgen del Rocio, Department of Internal Medicine, Sevilla, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez Nieto</LastName><ForeName>Jose Antonio</ForeName><Initials>JA</Initials><AffiliationInfo><Affiliation>Hospital Can Misses, Autoimmune Disease Unit, Internal Medicine, Ibiza, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Guiducci</LastName><ForeName>Serena</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jordan</LastName><ForeName>Suzana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, University Hospital Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Limaye</LastName><ForeName>Vidya</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Royal Adelaide Hospital, University of Adelaide, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maurer</LastName><ForeName>Britta</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, University Hospital Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selva-O'Callaghan</LastName><ForeName>Albert</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Vall D'Hebron General Hospital, Autonoma Univeristy of Barcelona, Internal Medicine, Barcelona, Spain; on behalf of GEAS-SEMI (Grupo Enfermedades Autoinmune Sistémicas)-(Sociedad Española de Medicina Interna).</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Riccieri</LastName><ForeName>Valeria</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Sapienza University of Rome, Department of Internal Medicine and Medical Specialities, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Distler</LastName><ForeName>Oliver</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Department of Rheumatology, University Hospital Zurich, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Matucci-Cerinic</LastName><ForeName>Marco</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Clinical and Experimental Medicine, AOUC, University of Florence, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Allanore</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Paris Descartes University, Rheumatology A Department, APHP, Cochin Hospital, Paris, France.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>Italy</Country><MedlineTA>Clin Exp Rheumatol</MedlineTA><NlmUniqueID>8308521</NlmUniqueID><ISSNLinking>0392-856X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>4F4X42SYQ6</RegistryNumber><NameOfSubstance UI="D000069283">Rituximab</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003240" MajorTopicYN="N">Connective Tissue Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="N">Lung</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017563" MajorTopicYN="N">Lung Diseases, Interstitial</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020127" MajorTopicYN="N">Recovery of Function</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069283" MajorTopicYN="N">Rituximab</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014797" MajorTopicYN="N">Vital Capacity</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2016</Year><Month>05</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2016</Year><Month>09</Month><Day>07</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">27749242</ArticleId><ArticleId IdType="pii">10723</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001854 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001854 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:27749242
|texte= Effects of rituximab in connective tissue disorders related interstitial lung disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:27749242" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |